NeoGenomics Laboratories, Inc. (NEO)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$16.59+1.22%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge NeoGenomics Laboratories, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+1.3%

+10% or more+5%0%−5%−10% or less

0.34 → 0.34 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	209.97M
EPS	—	0.07
FY 2026 · Annual
Revenue	$797M–$803M	805.18M
EPS	—	0.187
FY 2027 · Annual
Revenue	—	885.4M
EPS	—	0.343

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Successful launch and adoption of new cancer diagnostic assays	New cancer tests like RaDaR ST MRD support long-term growth.	Intact	new product launches fail to gain market traction or coverage	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 4 quarters. Management launched RaDaR ST MRD assay in early 2026 and submitted evidence for Medicare reimbursement in 2026-Q2. The company resolved patent litigation in 2025-Q4 and views these products as key long-term growth drivers. Progress is evident though revenue contribution from MRD is expected modest in 2026. Delivery assessment Oct 24, 2026
Reduce net loss and improve adjusted EBITDA	It cuts net loss by 34% and raises adjusted EBITDA 27%.	Improving	net loss reduction stalls or reverses; adjusted EBITDA fails to grow	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Adjusted EBITDA increased from $11 million in 2025-Q2 to $14 million in 2026-Q2 (36% increase). Net income improved from a loss of $45 million in 2025-Q2 to a net income of $2 million in 2026-Q2. Operating income loss narrowed from $47.6 million to $9.8 million over the same period. Management is delivering improved profitability and margin expansion consistent with stated goals. Delivery assessment Oct 24, 2026
Sustain double-digit revenue growth to at least $800 million in 2026	A primary condition in NeoGenomics Laboratories, Inc.'s published investment case. The stated target is >= $797 million.	Intact	annual revenue falls below $727 million (2025 level) in FY26	Revenue: $201.656M FY2026-Q2; GAAP. Published target: >= $797 million. Target period is not explicitly aligned with this observation. Source published Jul 28, 2026201,656,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 3be0c10b-641b-4439-b2bd-1f10005f9d6e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $181 million in 2025-Q2 to $202 million in 2026-Q2 (11% increase), with NGS revenue growth of 26% in 2026-Q2. Full year 2026 revenue guidance was raised to $802-$806 million, a 10%-11% increase over 2025 actuals. Management is delivering consistent double-digit revenue growth aligned with stated priorities. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.34

$0.36 → $0.34 · observed estimates

FY2027 revenue$0.89B

$0.88B → $0.89B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.36	$880,685,080	11 / 12
2026-07-25	$0.36	$880,685,080	11 / 12
2026-07-26	$0.36	$880,685,080	11 / 12
2026-07-27	$0.37	$880,685,080	11 / 12
2026-07-28	$0.37	$880,685,080	11 / 12
2026-07-29	$0.37	$880,685,080	11 / 12
2026-07-30	$0.37	$880,685,080	11 / 12
2026-07-31	$0.34	$884,794,300	11 / 12
2026-08-01	$0.34	$884,794,303	7 / 9
2026-08-02	$0.34	$884,794,303	7 / 9
2026-08-03	$0.34	$884,794,303	7 / 9
2026-08-04	$0.34	$884,794,300	11 / 12
2026-08-05	$0.34	$884,794,300	11 / 12
2026-08-06	$0.34	$884,794,303	7 / 9
2026-08-07	$0.34	$884,794,303	7 / 9
2026-08-08	$0.34	$884,794,300	11 / 12
2026-08-09	$0.34	$884,794,303	7 / 9
2026-08-10	$0.34	$884,794,300	11 / 12
2026-08-12	$0.34	$884,794,300	11 / 12
2026-08-13	$0.34	$884,794,303	7 / 9
2026-08-14	$0.34	$884,794,303	7 / 9
2026-08-15	$0.34	$884,794,303	7 / 9
2026-08-16	$0.34	$884,794,303	7 / 9
2026-08-17	$0.34	$884,794,303	7 / 9
2026-08-18	$0.34	$884,794,303	7 / 9
2026-08-19	$0.34	$884,794,303	7 / 9
2026-08-20	$0.34	$884,794,303	7 / 9
2026-08-21	$0.34	$884,794,303	7 / 9
2026-08-22	$0.34	$884,794,303	7 / 9
2026-08-23	$0.34	$884,794,303	7 / 9
2026-08-24	$0.34	$884,794,303	7 / 9
2026-08-25	$0.34	$884,794,303	7 / 9
2026-08-26	$0.34	$884,794,303	7 / 9
2026-08-27	$0.34	$884,794,303	7 / 9
2026-08-28	$0.34	$884,794,303	7 / 9
2026-08-29	$0.34	$884,791,553	7 / 9
2026-08-30	$0.34	$884,791,553	7 / 9
2026-08-31	$0.34	$884,791,553	7 / 9
2026-09-01	$0.34	$884,791,553	7 / 9
2026-09-02	$0.34	$884,791,553	7 / 9
2026-09-03	$0.34	$884,791,553	7 / 9
2026-09-04	$0.34	$884,791,553	7 / 9
2026-09-05	$0.34	$884,791,553	7 / 9
2026-09-06	$0.34	$884,791,553	7 / 9
2026-09-07	$0.34	$884,791,553	7 / 9
2026-09-08	$0.34	$884,791,553	7 / 9
2026-09-09	$0.34	$884,791,553	7 / 9
2026-09-10	$0.34	$884,791,553	7 / 9
2026-09-11	$0.34	$884,791,553	7 / 9
2026-09-12	$0.34	$884,791,553	7 / 9
2026-09-13	$0.34	$884,791,553	7 / 9
2026-09-14	$0.34	$884,791,553	7 / 9
2026-09-15	$0.34	$884,791,553	7 / 9
2026-09-16	$0.34	$884,791,553	7 / 9
2026-09-17	$0.34	$884,791,553	7 / 9
2026-09-18	$0.34	$884,791,553	7 / 9
2026-09-19	$0.34	$884,791,553	7 / 9
2026-09-20	$0.34	$884,791,553	7 / 9
2026-09-21	$0.34	$884,791,553	7 / 9
2026-09-22	$0.34	$884,791,553	7 / 9
2026-09-23	$0.34	$884,791,553	7 / 9
2026-09-24	$0.34	$884,791,553	7 / 9
2026-09-25	$0.34	$884,791,553	7 / 9
2026-09-26	$0.34	$884,791,553	7 / 9
2026-09-27	$0.34	$884,791,553	7 / 9
2026-09-28	$0.34	$884,791,553	7 / 9
2026-09-29	$0.34	$884,791,553	7 / 9
2026-09-30	$0.34	$884,791,553	7 / 9
2026-10-01	$0.34	$884,791,553	7 / 9
2026-10-02	$0.34	$884,791,553	7 / 9
2026-10-03	$0.34	$884,791,553	7 / 9
2026-10-04	$0.34	$884,791,553	7 / 9
2026-10-05	$0.34	$884,791,553	7 / 9
2026-10-06	$0.34	$884,791,553	7 / 9
2026-10-07	$0.34	$884,843,553	7 / 9
2026-10-08	$0.34	$885,084,410	7 / 9
2026-10-09	$0.34	$885,051,077	7 / 9
2026-10-10	$0.34	$885,051,077	7 / 9
2026-10-11	$0.34	$885,051,077	7 / 9
2026-10-12	$0.34	$885,051,077	7 / 9
2026-10-13	$0.34	$885,051,077	7 / 9
2026-10-14	$0.34	$885,403,827	7 / 9
2026-10-15	$0.34	$885,403,827	7 / 9
2026-10-16	$0.34	$885,403,827	7 / 9
2026-10-17	$0.34	$885,403,827	7 / 9
2026-10-18	$0.34	$885,403,827	7 / 9
2026-10-19	$0.34	$885,403,827	7 / 9
2026-10-20	$0.34	$885,403,827	7 / 9
2026-10-21	$0.34	$885,403,827	7 / 9
2026-10-22	$0.34	$885,403,827	7 / 9
2026-10-23	$0.34	$885,403,827	7 / 9
2026-10-24	$0.34	$885,403,827	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	6
2026-06-01	8	4
2026-07-01	8	4
2026-08-01	8	4
2026-09-01	8	4
2026-10-01	9	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

NeedhamOct 6

$22.00New observation · no comparable prior

BTIGOct 6

$28.00New observation · no comparable prior

$0$15.40$30.80

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Successful launch and adoption of new cancer diagnostic assaysQualitative condition
Reduce net loss and improve adjusted EBITDADirect metric needs a verified mapping
Sustain double-digit revenue growth to at least $800 million in 2026Revenue: $201.656M

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-45.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

NeoGenomics Laboratories, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

NEO is a growth-focused healthcare business with a still-developing profitability profile, rather than a proven durable compounder. Its multi-year thesis is intact, supported by recent results, but elevated risk and medium overall confidence call for caution in how firmly that view is held.

What's priced into NeoGenomics Laboratories, Inc.

The valuation evidence describes NEO as cheap versus peers, with a modest expectations gap and low model confidence. The priced-in assessment is tagged justified, with no fragility gates triggered; however, the valuation measure rose recently, so the evidence on valuation remains uncertain.

What the fundamentals likely do

Near term, recent results and guidance support continued revenue growth: second-quarter revenue rose 11% year over year, and full-year 2026 guidance was raised. Profitability also improved, with a small net profit in the quarter and a narrower operating loss, though the business remains loss-making on the broader earnings-quality measure. Cancer-test launches are progressing, but their revenue contribution is expected to be modest in 2026; the CEO transition and the company’s history of a deep miss remain watch points.

What NeoGenomics Laboratories, Inc. hinges on

The multi-year thesis depends on sustained revenue growth and continued progress toward stronger operating results, including whether newer cancer tests gain traction over time. Near term, reversing the recently raised guidance would weaken management credibility, while a weakening jobs picture could pressure cyclical healthcare names. Continued earnings strength from sector peers would support the sector backdrop, but would not by itself establish NEO’s execution.